ESR1 and prolactin-producing pituitary gland adenoma: Selective estrogen receptor modulators (SERMs) lower prolactin (PRL) levels by blocking estrogen’s effects on lactotroph cells, which can otherwise raise PRL and promote cell growth; in resistant prolactinomas, SERMs like tamoxifen and raloxifene have been shown to reduce PRL levels by 20%.